SCHEMBL2288930

SCHEMBL2288930

Cc1nc(CO)no1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427608 0.81
SCHEMBL12284250 0.79 L3MBTL1 (0.35)
SCHEMBL3796925 0.77
SCHEMBL469321 0.77
SCHEMBL12378572 0.75
SCHEMBL1170174 0.75
SCHEMBL18737647 0.75 L3MBTL1 (0.31)
SCHEMBL827849 0.73
SCHEMBL10146608 0.73 L3MBTL1 (0.32)
SCHEMBL991159 0.73 CHRM2 (0.36)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421224-B2 Azetidinyl O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors BIOGEN MA INC. (US) 2025-09-23 US disclosed
US-11851425-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines H. LUNDBECK A/S (DK) 2023-12-26 US disclosed
US-20230271964-A1 5-AMINO-8-(4-PYRIDYL)-[1,2,4]TRIAZOLO[4,3-C]PYRIMIDIN-3-ONE COMPOUNDS FOR USE AGAINST CANCER NXERA PHARMA UK LIMITED (GB) 2023-08-31 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
US-20230219938-A1 COMPOUNDS AND THEIR METHODS OF USE PRAXIS PREC MEDICINES INC (US) 2023-07-13 US disclosed
CN-111556871-B 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors H.隆德贝克有限公司 2023-07-07 CN disclosed
CN-111491936-B Macrocyclic compounds as PDE1 inhibitors H.隆德贝克有限公司 2023-07-04 CN disclosed
US-11634416-B2 Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines H. LUNDBECK A/S (DK) 2023-04-25 US disclosed
WO-2022262736-A1 BENZOXAZINONE DERIVATIVES 正大天晴药业集团股份有限公司 2022-12-22 WO disclosed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US disclosed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US disclosed
US-20080058315-A1 Integrase inhibitors GILEAD SCIENCES, INC. 2008-03-06 US disclosed
US-7335632-B2 Beta-secretase inhibitors and methods of use thereof COMENTIS, INC. (US) 2008-02-26 US disclosed
WO-2007136714-A2 INTEGRASE INHIBITORS GILEAD SCIENCES, INC. (US) 2007-11-29 WO disclosed
US-20070197628-A1 Cannabinoid receptor modulators INTERVET INTERNATIONAL B.V. (NL) 2007-08-23 US disclosed
WO-2006034296-A2 AMINO-CONTAINING COMPOUNDS WHICH INHIBIT MEMAPSIN 2 BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF COMENTIS, INC. (US) 2006-03-30 WO disclosed
EP-0915875-B1 SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES AS LIGANDS FOR GABA RECEPTORS MERCK SHARP & DOHME (GB) 2003-04-09 EP disclosed
US-6255305-B1 PSYCHOLOGICAL DISORDERS MERCK SHARP & DOHME LIMITED (GB) 2001-07-03 US disclosed
US-4160829-A ANTIBIOTICS GIST-BROCADES N.V. (NL) 1979-07-10 US disclosed